インフルエンザワクチンのアジア太平洋市場2020-2079

◆英語タイトル:ASIA PACIFIC INFLUENZA VACCINE MARKET FORECAST 2020-2028
◆商品コード:INK20MY130
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2020年4月
◆ページ数:116
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:アジア太平洋
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥131,250見積依頼/購入/質問フォーム
Multi LicenseUSD1,500 ⇒換算¥157,500見積依頼/購入/質問フォーム
Enterprisewide PriceUSD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Inkwood Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

KEY FINDINGSThe Asia Pacific influenza vaccine market is evaluated to record a CAGR of 6.92% during the estimated period of 2020-2028. The various factors contributing to the growth of the market in the region are the rising geriatric population, government initiatives, birth rates, and high awareness, and government funding to develop vaccines.

MARKET INSIGHTS
The Asia Pacific influenza vaccine market growth is further analyzed by segmenting the region into Japan, Thailand, Australia & New Zealand, India, Vietnam, China, Indonesia, South Korea, and the rest of Asia Pacific that includes Taiwan, Malaysia, Sri Lanka, and others. Australia experienced its most aggressive flu season in 2019, with more than 31,000 people reporting to hospitals and health services all over the country. In New Zealand, more than 200,000 people contract flu every year. Influenza is probably the worst infectious disease in New Zealand. So influenza vaccines are highly required in Australia & New Zealand. In Thailand, most of the influenza patients range from young to school-age children. The DDC expects influenza spread to be high due to a drop in temperature.
In Indonesia, the fatality rate of human A/H5N1 cases is high, but the clinical and epidemiological data states that the influenza virus has limited circulation among humans. A study is conducted to characterize and compare the clinical and epidemiological patterns of influenza virus in humans through surveillance among patients with ILI in Bali. Vietnam is vulnerable to serious and emerging zoonotic and infectious diseases like SARS, H5N1, H5N6, and H1N1. The government of Vietnam and USAID is promoting early detection and warning of avian and influenza outbreaks through improved regional and national preparedness. The dense population and economic activities of the rest of Asia Pacific countries will help the market grow.

COMPETITIVE INSIGHTS
Sanofi, CSL Limited, BioDiem, Abbott, Pfizer Inc, etc. are some of the well-established companies operating in the region.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

【レポートの目次】

1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES `
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. PARENT MARKET ANALYSIS: VACCINE MARKET
3.2. MARKET DEFINITION
3.3. KEY DRIVERS
3.3.1. GOVERNMENT IMMUNIZATION PROGRAMS TO ERADICATE AILMENTS FROM THE SOCIETY
3.3.2. RISE IN THE CASES OF INFLUENZA
3.3.3. TECHNOLOGY ADVANCEMENT
3.4. KEY RESTRAINTS
3.4.1. HIGH COST OF DEVELOPMENT
3.4.2. LENGTHY PROCESS OF DEVELOPMENT
4. KEY ANALYTICS
4.1. KEY INVESTMENT INSIGHTS
4.2. PORTER’S FIVE FORCE ANALYSIS
4.2.1. BUYER POWER
4.2.2. SUPPLIER POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. OPPORTUNITY MATRIX
4.4. VENDOR LANDSCAPE
5. MARKET BY TYPE
5.1. QUADRIVALENT VACCINE
5.2. TRIVALENT VACCINE
6. MARKET BY TECHNOLOGY
6.1. EGG-BASED TECHNOLOGY
6.2. CELL-BASED TECHNOLOGY
7. MARKET BY AGE GROUP
7.1. PEDIATRIC AGE GROUP
7.2. ADULT AGE GROUP
8. MARKET BY DELIVERY MODE
8.1. INJECTION
8.2. NASAL SPRAY
9. GEOGRAPHICAL ANALYSIS
9.1. ASIA PACIFIC
9.1.1.1. CHINA
9.1.1.2. JAPAN
9.1.1.3. INDIA
9.1.1.4. SOUTH KOREA
9.1.1.5. AUSTRALIA & NEW ZEALAND
9.1.1.6. THAILAND
9.1.1.7. INDONESIA
9.1.1.8. VIETNAM
9.1.1.9. REST OF ASIA PACIFIC
10. COMPANY PROFILES
10.1. MERCK
10.2. NOVARTIS AG
10.3. PFIZER INC
10.4. SANOFI
10.5. BIODIEM
10.6. EMERGENT BIOSOLUTIONS
10.7. F. HOFFMANN-LA ROCHE LTD
10.8. GLAXOSMITHKLINE
10.9. ABBOTT
10.10. CSL LTD



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[インフルエンザワクチンのアジア太平洋市場2020-2079]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆